Evidence map›Paper›PMID 29747472›Full record

ArticlePharmaceutics2018

Combining MucilAir™ and Vitrocell

Julia Metz, Katharina Knoth, Henrik Groß, Claus-Michael Lehr, Carolin Stäbler, Udo Bock, Marius Hittinger

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. A Model of Human Small Airway on a Chip for Studies of Subacute Effects of Inhalation Toxicants.Toxicological sciences : an official journal of the Society of Toxicology · 2022
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Julia MetzDepartment of Drug Delivery, PharmBioTec GmbH, 66123 Saarbrücken, Germany. j.metz@pharmbiotec.de.
Katharina KnothDepartment of Drug Delivery, PharmBioTec GmbH, 66123 Saarbrücken, Germany. k.knoth@pharmbiotec.de.
Henrik GroßDepartment of Drug Delivery, PharmBioTec GmbH, 66123 Saarbrücken, Germany. h.gross@pharmbiotec.de.
Claus-Michael LehrDepartment of Drug Delivery, PharmBioTec GmbH, 66123 Saarbrücken, Germany. Claus-Michael.Lehr@helmholtz-hzi.de.
Carolin StäblerDepartment of Scientific Affairs Consumer Health, Bayer Vital GmbH, 51368 Leverkusen, Germany. carolin.staebler@bayer.com.
Udo BockBock Project Management, 54456 Tawern, Germany. udo.bock@bock-pm.com.
Marius HittingerDepartment of Drug Delivery, PharmBioTec GmbH, 66123 Saarbrücken, Germany. m.hittinger@pharmbiotec.de.
Bayer (Germany) · DEHelmholtz Institute for Pharmaceutical Research Saarland · DESaarland University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hay fever is notoriously triggered when nasal mucosa is exposed to allergenic pollen. One possibility to overcome this pollen exposure may be the application of an ointment with physical protective effects. In this context, we have investigated Bepanthen

Indexed as

aerosol deposition in vitro systemallergy preventionBepanthen® Eye and Nose Ointmentnasal mucosapollen

Identifiers

PMID29747472
PMCPMC6027377
OpenAlexW2800879624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.